CCP
INDV icon

Corbin Capital Partners’s Indivior Pharmaceuticals INDV Stock Holding History

Corbin Capital Partners’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-199,574
Closed -$3.38M – 32
2024
Q2 		$3.38M Hold
199,574
– – 6.52% 4
2024
Q1 		$3.38M Hold
199,574
– – 5.72% 4
2023
Q4 		$2.36M Hold
199,574
– – 9.89% 5
2023
Q3 		$3.55M Hold
199,574
– – 5.26% 5
2023
Q2 		$3.64M Buy
+199,574
New +$4.57M 3.07% 10

Other funds holding INDV

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
LIP
Liontrust Investment Partners London, United Kingdom $6.8B AUM 23.31% 1-Year Est. Return

Corbin Capital Partners's INDV Position: Q3 2024 in Review

Corbin Capital Partners sold out of Indivior Pharmaceuticals (INDV) in Q3 2024, closing a stake of 199,574 shares — an estimated $3.38M sold.

Corbin Capital Partners first reported a position in INDV in Q2 2023 and held it in 5 quarters. The position peaked at $3.64M in Q2 2023. 103 funds tracked by Wall St. Rank hold INDV as of Q3 2024.

  • Corbin Capital Partners reported no remaining Indivior Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Corbin Capital Partners sold 199,574 Indivior Pharmaceuticals shares in Q3 2024, an estimated $3.38M.
  • Corbin Capital Partners first reported a position in Indivior Pharmaceuticals in Q2 2023 and held it in 5 quarters.
  • Corbin Capital Partners's Indivior Pharmaceuticals position peaked at $3.64M in Q2 2023.
  • 103 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q3 2024.

Based on Corbin Capital Partners's 13F filing for Q3 2024, filed 12 Nov 2024.